Regenerative & personalized

Nineteen subjects that mix hardware, cells and data, and keep returning to the same ideas. The interface decides. An implant’s working life is set by how tissue reacts to it and by a stiffness mismatch at the boundary, not by material strength; what happens on a device surface in the first seconds decides what grows around it a month later; a chronic neural electrode loses its signal to the glial scar, not to its electronics.

A preparation is a population, not a product. Exosome therapy’s real problem is potency, not yield; infused mesenchymal cells mostly die in the lung within hours — and the best current account says that is the mechanism; a two-channel headband reads exactly what two dry electrodes can read, no more.

A batch of one is a scientific problem. Personalised medicine has to say what a single outcome can and cannot establish — the same discipline a digital twin obeys when it substitutes for a measurement without creating information about effect.

Start with personalised regenerative medicine: it states why n-of-one is the field’s defining constraint; the interface and neurotechnology pages then show what the body does to anything placed in or on it.

Bio products for intimate health Acidity, colonisation resistance and biofilm: the mechanism vaginal probiotics rest on, and engraftment as the point where the category most often fails to hold up.
Biomedical engineering and implants The foreign-body response, modulus mismatch and interface wear — the three mechanisms that decide how long orthopaedic, cardiovascular and neural implants last.
Cognitive performance optimisation Adenosine blockade, the brain's energy buffer and a genotype-dependent dopamine optimum — the mechanisms that survive scrutiny, and the null replications that are findings in their own right.
Geroscience and senolytics Senescence as a secretory phenotype, anti-apoptotic dependence as the target, and intermittent dosing as a direct consequence of killing rather than modulating.
Neural interfaces Signal-to-noise as a function of distance from the neuron, the glial scar and rising impedance as the real limit on implant life, and the invasiveness-bandwidth trade-off.
Patient digital twins and in silico trials Mechanistic pharmacokinetics, the prognostic covariate, and the context of use — what a digital twin actually computes and where its formal limit lies.
Xenotransplantation The triple carbohydrate knockout, coagulation incompatibility on pig endothelium, and latent porcine cytomegalovirus as the actual variable deciding graft survival.
Biomimetic medical adhesives The interfacial chemistry of adhesion in a wet, moving, living field — catechol groups, coacervates, and the adhesion-cohesion trade-off that sets the ceiling on surgical sealants.
Consumer neurotech and wellness BCI/EEG The biophysics of scalp EEG — what generates the signal, why the skull blurs it, and how electrode count and dry-contact impedance bound what a consumer headset can honestly claim.
Exosome therapy and extracellular vesicles How extracellular vesicles are made and taken up, why no separation method resolves them cleanly, and why an undefined active substance blocks the step from promising biology to a dosed medicine.
In vitro gametogenesis and reproductive synbio Germ-cell specification, the genome-wide erasure and rewriting of DNA methylation, and the meiotic checkpoints that make in vitro gametogenesis far harder in humans than in mice.
Organ and tissue bioprinting Bioink rheology, shear damage and sacrificial vasculature — and why the oxygen diffusion limit turns a printed organ into a transport and anastomosis problem rather than a printing one.
Personalized nutrition Postprandial variability between individuals, the microbiome's contribution to it, and the evidence gap between a measured difference in glucose response and a recommendation engine.
Bioelectronic medicine and neuromodulation The inflammatory reflex, the physics of capturing an axon with an extracellular field, and the selectivity problem of a mixed nerve — the constraints that set the ceiling on electroceuticals.
Bionic prostheses and neuroprosthetics Surface EMG and its crosstalk ceiling, targeted muscle reinnervation as a biological amplifier of intent, osseointegration as a mechanical and infection problem, and the missing afferent loop.
Digital therapeutics Digital therapeutics as delivery of a validated behavioural protocol, the blinding and placebo problem in a software RCT, and engagement decay as the pharmacokinetics of a digital drug.
Medical device biointerfaces Protein adsorption and the Vroman sequence, the foreign-body response, fibrous encapsulation, haemocompatibility and surface modification: the chemistry of the material–tissue boundary rather than the design of the device.
Partial epigenetic reprogramming Transient OSK/OSKM expression, resetting DNA methylation age without passing through pluripotency, teratoma risk as the dose-limiting constraint, and the unresolved question of whether an epigenetic clock reads a cause or a correlate.
Personalised regenerative medicine Autologous versus allogeneic as a trade between immunology and manufacturing: the batch of one, release testing with no time for a sterility culture, starting-material variability, and universal-donor engineering.